BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 32439095)

  • 1. Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19.
    Bozkurt B; Kovacs R; Harrington B
    J Card Fail; 2020 May; 26(5):370. PubMed ID: 32439095
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence.
    Turgeon RD; Zieroth S; Bewick D; Chow CM; Clarke B; Cowan S; Fordyce CB; Fournier A; Gin K; Gupta A; Hardiman S; Jackson S; Lau B; Leong-Poi H; Mansour S; Marelli A; Quraishi AR; Roifman I; Ruel M; Sapp J; Singh G; Small G; Virani S; Wood DA; Krahn A
    Can J Cardiol; 2020 Aug; 36(8):1180-1182. PubMed ID: 32502522
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.
    Brojakowska A; Narula J; Shimony R; Bander J
    J Am Coll Cardiol; 2020 Jun; 75(24):3085-3095. PubMed ID: 32305401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?
    Vitiello A; Ferrara F
    Eur J Pharmacol; 2020 Sep; 883():173373. PubMed ID: 32679185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.
    Siniorakis E; Arvanitakis S; Nikolopoulos I; Elkouris M
    mBio; 2020 May; 11(3):. PubMed ID: 32444383
    [No Abstract]   [Full Text] [Related]  

  • 6. Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.
    Wang JJ; Edin ML; Zeldin DC; Li C; Wang DW; Chen C
    Pharmacol Ther; 2020 Nov; 215():107628. PubMed ID: 32653530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular disease and the impact of COVID-19.
    Yoganathan A; Sajjad MS; Harky A
    J Card Surg; 2020 Aug; 35(8):2113. PubMed ID: 32542799
    [No Abstract]   [Full Text] [Related]  

  • 8. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea.
    Son M; Seo J; Yang S
    Hypertension; 2020 Sep; 76(3):742-749. PubMed ID: 32654557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19: The heart of the issue.
    Woodward B; Kermali M
    J Card Surg; 2020 Aug; 35(8):2112. PubMed ID: 32542802
    [No Abstract]   [Full Text] [Related]  

  • 10. Drugs and the renin-angiotensin system in covid-19.
    Aronson JK; Ferner RE
    BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880
    [No Abstract]   [Full Text] [Related]  

  • 11. The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19.
    Tsioufis C; Dimitriadis K; Tousoulis D
    Hellenic J Cardiol; 2020; 61(1):31-33. PubMed ID: 32450334
    [No Abstract]   [Full Text] [Related]  

  • 12. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease.
    Tomasoni D; Italia L; Adamo M; Inciardi RM; Lombardi CM; Solomon SD; Metra M
    Eur J Heart Fail; 2020 Jun; 22(6):957-966. PubMed ID: 32412156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.
    Conversano A; Melillo F; Napolano A; Fominskiy E; Spessot M; Ciceri F; Agricola E
    Hypertension; 2020 Aug; 76(2):e10-e12. PubMed ID: 32383626
    [No Abstract]   [Full Text] [Related]  

  • 14. Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension.
    Iaccarino G; Grassi G; Borghi C; Ferri C; Salvetti M; Volpe M;
    Hypertension; 2020 Aug; 76(2):366-372. PubMed ID: 32564693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.
    Furuhashi M; Moniwa N; Takizawa H; Ura N; Shimamoto K
    Hypertens Res; 2020 Aug; 43(8):837-840. PubMed ID: 32433641
    [No Abstract]   [Full Text] [Related]  

  • 16. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Coronavirus Disease 2019: Friend or Foe?
    Shyh GI; Nawarskas JJ; Cheng-Lai A
    Cardiol Rev; 2020; 28(4):213-216. PubMed ID: 32496364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controversy regarding ACE inhibitors / ARBs in COVID-19.
    Soria Arcos F; Romero Puche A; Vicente Vera T
    Rev Esp Cardiol (Engl Ed); 2020 Jun; 73(6):516. PubMed ID: 32371022
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19.
    Kow CS; Zaidi STR; Hasan SS
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):217-221. PubMed ID: 32281055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The RAAS and SARS-CoV-2: A riddle to solve].
    Choi M; Aiello EA; Ennis IL; Villa-Abrille MC
    Hipertens Riesgo Vasc; 2020; 37(4):169-175. PubMed ID: 32527699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers are not associated with increased risk of SARS-CoV-2 infection.
    Chodick G; Nutman A; Yiekutiel N; Shalev V
    J Travel Med; 2020 Aug; 27(5):. PubMed ID: 32406512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.